Ovoca Bio (DUB:OVXA) ROCE % : -74.22% (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ovoca Bio's annualized ROCE % for the quarter that ended in Jun. 2023 was -74.22%.

Ovoca Bio ROCE % Historical Data

The historical data trend for Ovoca Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio ROCE % Chart

Ovoca Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-9.23

-8.45

-10.86

-32.68

-52.91

Ovoca Bio Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-35.24	-29.01	-102.16	1.77	-74.22

Ovoca Bio ROCE % Calculation

Ovoca Bio's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-5.573	/	( ( (14.771 - 1.341)	+	(9.405 - 1.77) )	/ 2 )
	=	-5.573	/	( (13.43	+	7.635)	/ 2 )
	=	-5.573	/	10.5325
	=	-52.91 %

Ovoca Bio's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-4.71	/	( ( (9.405 - 1.77)	+	(5.877 - 0.82) )	/ 2 )
	=	-4.71	/	( ( 7.635	+	5.057 )	/ 2 )
	=	-4.71	/	6.346
	=	-74.22 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Ovoca Bio (DUB:OVXA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ovoca Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio (DUB:OVXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OVB.GB:UK OVB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines